The rise of Sildenafil initially drove a boom for pharma, but recent developments present a uncertain outlook for investors. Lower-cost versions are eroding profits, and continued patent challenges add further https://lawsonyunv697843.vblogetin.com/47270423/sildenafil-and-pharma-a-volatile-bet